Investigating how Type 3 Innate Lymphoid Cells affect melanoma tumors
The frequency and function of Type 3 Innate Lymphoid Cells regulates the melanoma tumor microenvironment
This study is looking at how certain immune cells called ILC3s behave in melanoma tumors to see if they affect how well treatments work, especially for patients who haven't had success with current therapies, with the hope of finding better ways to help them.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Duke University NIH-funded |
| Lab location | 1 site (Durham, United States) |
| Project ID | NIH-10993053 on NIH RePORTER |
What this research studies
This research explores the role of Type 3 Innate Lymphoid Cells (ILC3s) in the melanoma tumor microenvironment. It aims to understand how these cells influence immune responses and contribute to the effectiveness of immune checkpoint inhibitors in treating advanced melanoma. By examining the interactions between ILC3s and other immune cells, the study seeks to identify potential mechanisms that lead to treatment resistance in patients. The findings could help tailor more effective therapies for melanoma patients who currently do not respond to existing treatments.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults with advanced melanoma, especially those who have not responded to immune checkpoint inhibitor therapy.
Not a fit: Patients with early-stage melanoma or those who have not undergone immune checkpoint inhibitor therapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment strategies for melanoma patients, particularly those who do not respond to current therapies.
How similar studies have performed: Previous research has shown promising results in understanding the role of immune cells in cancer treatment, suggesting that this approach could yield valuable insights.
Where this research is happening
Durham, United States
- Duke University — Durham, United States (Active)
Researchers
- Principal investigator: O'connor, Margaret — Duke University
- Study coordinator: O'connor, Margaret
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.